BackCytokinetics Overview
Cytokinetics Inc

Cytokinetics Target Price

See Cytokinetics's analyst price targets ($110) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$56.13

Average Target Price

$110.5096.9% upside

6 analysts in the last 4 months

High: $113 | Low: $104

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-10-14UBSAshwani Verma$10485.3% upsideOpen
2026-10-08RBC CapitalLeonid Timashev$113101.3% upsideOpen
2026-08-13Barclays$11096% upsideOpen
2026-08-10Truist FinancialSrikripa Devarakonda$11299.5% upsideOpen
2026-08-07RBC CapitalLeonid Timashev$11299.5% upsideOpen
2026-08-07NeedhamSerge Belanger$11299.5% upsideOpen
2026-07-07RBC CapitalLeonid Timashev$117108.4% upsideOpen
2026-06-29UBSAshwani Verma$115104.9% upsideOpen
2026-06-24Mizuho Securities$118110.2% upsideOpen
2026-06-17RBC CapitalLeonid Timashev$119112% upsideOpen
2026-05-11H.C. Wainwright$140149.4% upsideOpen
2026-05-06Stifel Nicolaus$10892.4% upsideOpen
2026-05-06UBS$119112% upsideOpen
2026-05-06Morgan Stanley$10383.5% upsideOpen
2026-05-05Truist FinancialSrikripa Devarakonda$10688.8% upsideOpen
2026-04-10Wells Fargo$9569.2% upsideOpen
2026-03-10Robert W. BairdRoanna Ruiz$8449.7% upsideOpen
2026-03-06UBSAshwani Verma$6922.9% upsideOpen
2026-02-20RBC Capital$10179.9% upsideOpen
2026-02-03Truist FinancialSrikripa Devarakonda$9263.9% upsideOpen
2026-01-09JefferiesAkash Tewari$9060.3% upsideOpen
2026-01-08Morgan StanleyMaxwell Skor$9060.3% upsideOpen
2025-12-22Truist FinancialSrikripa Devarakonda$8449.7% upsideOpen
2025-12-22Morgan Stanley$7126.5% upsideOpen
2025-12-22Leerink PartnersRoanna Ruiz$8347.9% upsideOpen
2025-12-22RBC Capital$9569.2% upsideOpen
2025-12-22NeedhamSerge Belanger$8449.7% upsideOpen
2025-12-22Goldman Sachs$9976.4% upsideOpen
2025-12-22H.C. WainwrightJoseph Pantginis$136142.3% upsideOpen
2025-12-22Barclays$8755% upsideOpen
2025-12-18Goldman Sachs$9569.2% upsideOpen
2025-12-01UBSAshwani Verma$618.7% upsideOpen
2025-10-06BarclaysGena Wang$8246.1% upsideOpen
2025-09-03Evercore ISICory Kasimov$8042.5% upsideOpen
2025-09-03BarclaysGena Wang$7126.5% upsideOpen
2025-09-02Stifel NicolausJames Condulis$9671% upsideOpen
2025-04-24BarclaysGena Wang$552% downsideOpen
2025-03-07Morgan Stanley$6719.4% upsideOpen
2024-10-17H.C. WainwrightJoseph Pantginis$120113.8% upsideOpen
2024-09-03Goldman SachsPaul Choi$606.9% upsideOpen
2024-06-10Piper SandlerYasmeen Rahimi$10790.6% upsideOpen
2024-06-04B.Riley FinancialMayank Mamtani$9263.9% upsideOpen
2024-05-28JMP SecuritiesJason Butler$7839% upsideOpen
2024-05-23H.C. WainwrightJoseph Pantginis$9060.3% upsideOpen
2024-05-23NeedhamSerge Belanger$7228.3% upsideOpen
2024-05-23JefferiesAkash Tewari$8551.4% upsideOpen
2024-05-23BarclaysCarter Gould$9569.2% upsideOpen
2024-05-09OppenheimerJustin Kim$10688.8% upsideOpen
2024-05-09JMP SecuritiesJason Butler$10688.8% upsideOpen
2024-04-05Mizuho SecuritiesSalim Syed$9976.4% upsideOpen

Cytokinetics (CYTK) FAQ

Cytokinetics posts a target price of $110. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

A target price of $110 for CYTK means covering analysts, on average, see the stock 96.9% upside of $56.13 over about 12 months. Dig into who set the high and low targets and how recently they updated — freshness matters as much as the average itself.

Context for CYTK's target price usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Cytokinetics's other metric pages and overview cover the third.

Judging Cytokinetics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in target price easier to interpret. Start with $110 here, then scan peer and history charts to see if the gap is persistent.